Granted Patent
B2
US 7,820,677 · App. 11/359,152 · Granted Oct 26, 2010
Phosphoric acid addition salt of (2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyridinyl]oxy}-ethoxy)-2-pyrazinyl]-2-methylpiperazine
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Stable acid addition salts of certain 2,3-disubstituted pyrazine compounds that are selective for the 5-HT2c receptor and therapeutically active in the central nervous system are described.
Claims (4)
1. A compound of the formula (Ib)
wherein R 1 , R 2 and R 3 are each hydrogen, R 4 is 2-dimethylaminoethoxy, and HA is phosphoric acid.
2. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
3. A method of making a pharmaceutical composition comprising combining the compound of claim 1 with a pharmaceutically acceptable carrier.
Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 2, 2014
From: BIOVITRUM AB (PUBL)
To: PROXIMAGEN NEUROSCIENCE PLC
Reel/Frame 031873/0532 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 2, 2014
From: PROXIMAGEN NEUROSCIENCE PLC
To: PROXIMAGEN LIMITED
Reel/Frame 031875/0869 →
CHANGE OF NAME
Recorded Jun 20, 2011
From: BIOVITRUM AB
To: BIOVITRUM AB (PUBL)
Reel/Frame 026480/0454 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 17, 2011
From: FLECK, TOM; CERNERUD, MAGNUS; LUNDSTROM, HELENA; LOFSTROM, CLAES; PELCMAN, MARGIT; PAPTCHIKHINE, ALEXANDER; ANDERSSON, EMMA; NYGREN, ALF
To: BIOVITRUM AB
Reel/Frame 026462/0949 →